title: Inhibition of RANK ligand: a new option for preventing fragility fractures.
abstract: Cortical and trabecular bone undergo a continuous and balanced remodeling process, consisting of an osteoclast-mediated bone-resorption phase and an osteoblast- mediated bone-formation phase. An imbalance in this process, which favours bone resorption, results in bone loss and in damage to the skeletal microarchitecture. A new targeted anti-resorptive approach is represented by the inhibition of RANK ligand (RANKL), which is one of the primary mediators of osteoclast activity, essential for osteoclast formation, function and survival.
authors.affiliation: Department of Orthopedics and Rehabilitation, Second University of Naples, Italy. giovanni.iolascon@unina2.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Iolascon
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Resmini
authors.forename: Umberto
authors.initials: U
authors.lastname: Tarantino
mesh_terms: D001862:Bone Resorption; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology; D002986:Clinical Trials as Topic; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D008954:Models, Biological; D010010:Osteoclasts / Q000378:metabolism; D053245:RANK Ligand / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D053245:RANK Ligand